Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies
Artikel i vetenskaplig tidskrift, 2014
Development of therapeutics for brain disorders is one of the more difficult challenges to be overcome by the scientific community due to the inability of most molecules to cross the blood-brain barrier (BBB). Antibody-conjugated nanoparticles are drug carriers that can be used to target encapsulated drugs to the brain endothelial cells and have proven to be very promising. They significantly improve the accumulation of the drug in pathological sites and decrease the undesirable side effect of drugs in healthy tissues. We review the systems that have demonstrated promising results in crossing the BBB through receptor-mediated endocytic mechanisms for the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease.
transferrin-receptor
in-vivo
enable drug-delivery
sterically stabilized liposomes
amyloid-beta peptide
gene-therapy
antitransferrin receptor antibody
rat-brain
alzheimers-disease
central-nervous-system
Författare
J. A. Loureiro
Universidade do Porto
Bárbara Gomes
Universidade do Porto
M. A. N. Coelho
Universidade do Porto
M. C. Pereira
Universidade do Porto
Sandra Rocha
Chalmers, Kemi- och bioteknik, Fysikalisk kemi
Nanomedicine
1743-5889 (ISSN) 1748-6963 (eISSN)
Vol. 9 5 709-722Ämneskategorier (SSIF 2011)
Biologiska vetenskaper
DOI
10.2217/NNM.14.27